{"id":19148,"date":"2024-04-01T14:37:44","date_gmt":"2024-04-01T17:37:44","guid":{"rendered":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/r3767-onc-2011-melanoma-metastatico-ou-localmente-avancado-e-irressecavel\/"},"modified":"2024-04-01T14:37:44","modified_gmt":"2024-04-01T17:37:44","slug":"r3767-onc-2011-melanoma-metastatico-ou-localmente-avancado-e-irressecavel","status":"publish","type":"ensaio_clinico","link":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/r3767-onc-2011-melanoma-metastatico-ou-localmente-avancado-e-irressecavel\/","title":{"rendered":"R3767-ONC-2011 &#8211; Melanoma metast\u00e1tico ou localmente avan\u00e7ado e irressec\u00e1vel"},"content":{"rendered":"<p>Fianlimabe + Cemiplimabe em compara\u00e7\u00e3o com Pembrolizumabe.<\/p>\n<p><strong>Popula\u00e7\u00e3o: <\/strong>Melanoma irressec\u00e1vel em est\u00e1gio III e IV, que n\u00e3o receberam terapia sist\u00eamica pr\u00e9via para doen\u00e7a irressec\u00e1vel avan\u00e7ada. <em>Crit\u00e9rio de exclus\u00e3o:<\/em> melanoma uveal.<\/p>\n<p>ClinicalTrials.gov: NCT05352672<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Fianlimabe + Cemiplimabe em compara\u00e7\u00e3o com Pembrolizumabe. Popula\u00e7\u00e3o: Melanoma irressec\u00e1vel em est\u00e1gio III e IV, que n\u00e3o receberam terapia sist\u00eamica pr\u00e9via para doen\u00e7a irressec\u00e1vel avan\u00e7ada. Crit\u00e9rio de exclus\u00e3o: melanoma uveal. ClinicalTrials.gov: NCT05352672<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false},"class_list":["post-19148","ensaio_clinico","type-ensaio_clinico","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>R3767-ONC-2011 - Melanoma metast\u00e1tico ou localmente avan\u00e7ado e irressec\u00e1vel - IDOR - Instituto D&#039;Or de Pesquisa e Ensino<\/title>\n<link rel=\"canonical\" href=\"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/r3767-onc-2011-melanoma-metastatico-ou-localmente-avancado-e-irressecavel\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"R3767-ONC-2011 - Melanoma metast\u00e1tico ou localmente avan\u00e7ado e irressec\u00e1vel - IDOR - Instituto D&#039;Or de Pesquisa e Ensino\" \/>\n<meta property=\"og:description\" content=\"Fianlimabe + Cemiplimabe em compara\u00e7\u00e3o com Pembrolizumabe. Popula\u00e7\u00e3o: Melanoma irressec\u00e1vel em est\u00e1gio III e IV, que n\u00e3o receberam terapia sist\u00eamica pr\u00e9via para doen\u00e7a irressec\u00e1vel avan\u00e7ada. Crit\u00e9rio de exclus\u00e3o: melanoma uveal. ClinicalTrials.gov: NCT05352672\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/r3767-onc-2011-melanoma-metastatico-ou-localmente-avancado-e-irressecavel\/\" \/>\n<meta property=\"og:site_name\" content=\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/pesquisa\\\/ensaiosclinicos\\\/r3767-onc-2011-melanoma-metastatico-ou-localmente-avancado-e-irressecavel\\\/\",\"url\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/pesquisa\\\/ensaiosclinicos\\\/r3767-onc-2011-melanoma-metastatico-ou-localmente-avancado-e-irressecavel\\\/\",\"name\":\"R3767-ONC-2011 - Melanoma metast\u00e1tico ou localmente avan\u00e7ado e irressec\u00e1vel - IDOR - Instituto D&#039;Or de Pesquisa e Ensino\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/#website\"},\"datePublished\":\"2024-04-01T17:37:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/pesquisa\\\/ensaiosclinicos\\\/r3767-onc-2011-melanoma-metastatico-ou-localmente-avancado-e-irressecavel\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/pesquisa\\\/ensaiosclinicos\\\/r3767-onc-2011-melanoma-metastatico-ou-localmente-avancado-e-irressecavel\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/pesquisa\\\/ensaiosclinicos\\\/r3767-onc-2011-melanoma-metastatico-ou-localmente-avancado-e-irressecavel\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/ptbr.idor.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ensaios Cl\u00ednicos\",\"item\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"R3767-ONC-2011 &#8211; Melanoma metast\u00e1tico ou localmente avan\u00e7ado e irressec\u00e1vel\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/#website\",\"url\":\"https:\\\/\\\/ptbr.idor.org\\\/\",\"name\":\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ptbr.idor.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"R3767-ONC-2011 - Melanoma metast\u00e1tico ou localmente avan\u00e7ado e irressec\u00e1vel - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","canonical":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/r3767-onc-2011-melanoma-metastatico-ou-localmente-avancado-e-irressecavel\/","og_locale":"pt_BR","og_type":"article","og_title":"R3767-ONC-2011 - Melanoma metast\u00e1tico ou localmente avan\u00e7ado e irressec\u00e1vel - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","og_description":"Fianlimabe + Cemiplimabe em compara\u00e7\u00e3o com Pembrolizumabe. Popula\u00e7\u00e3o: Melanoma irressec\u00e1vel em est\u00e1gio III e IV, que n\u00e3o receberam terapia sist\u00eamica pr\u00e9via para doen\u00e7a irressec\u00e1vel avan\u00e7ada. Crit\u00e9rio de exclus\u00e3o: melanoma uveal. ClinicalTrials.gov: NCT05352672","og_url":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/r3767-onc-2011-melanoma-metastatico-ou-localmente-avancado-e-irressecavel\/","og_site_name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/r3767-onc-2011-melanoma-metastatico-ou-localmente-avancado-e-irressecavel\/","url":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/r3767-onc-2011-melanoma-metastatico-ou-localmente-avancado-e-irressecavel\/","name":"R3767-ONC-2011 - Melanoma metast\u00e1tico ou localmente avan\u00e7ado e irressec\u00e1vel - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","isPartOf":{"@id":"https:\/\/ptbr.idor.org\/#website"},"datePublished":"2024-04-01T17:37:44+00:00","breadcrumb":{"@id":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/r3767-onc-2011-melanoma-metastatico-ou-localmente-avancado-e-irressecavel\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/r3767-onc-2011-melanoma-metastatico-ou-localmente-avancado-e-irressecavel\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/r3767-onc-2011-melanoma-metastatico-ou-localmente-avancado-e-irressecavel\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/ptbr.idor.org\/"},{"@type":"ListItem","position":2,"name":"Ensaios Cl\u00ednicos","item":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/"},{"@type":"ListItem","position":3,"name":"R3767-ONC-2011 &#8211; Melanoma metast\u00e1tico ou localmente avan\u00e7ado e irressec\u00e1vel"}]},{"@type":"WebSite","@id":"https:\/\/ptbr.idor.org\/#website","url":"https:\/\/ptbr.idor.org\/","name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ptbr.idor.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"}]}},"_links":{"self":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico\/19148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico"}],"about":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/types\/ensaio_clinico"}],"wp:attachment":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/media?parent=19148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}